Inhibrx Biosciences, Inc.INBXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

seekingalpha.com

Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too

Inhibrx Biosciences, Inc. remains a Strong Buy, driven by multiple near-term catalysts, notably the Q2 2026 BLA filing for ozekibart in chondrosarcoma. INBX expects to release pivotal progression-free survival [PFS] data for ozekibart + FOLFIRI in heavily pretreated metastatic colorectal cancer in 2026. Ozekibart is also advancing in Ewing Sarcoma, with enrollment completion expected Q2 2026 and potential FDA meeting for accelerated approval in H2 2026.

benzinga.com

Why Inhibrx's Recent Strength May Not Be Built to Last

Inhibrx (NASDAQ: INBX) has staged a sharp rally after reporting positive topline results from its registrational trial of Ozekibart (INBRX-109) back in October 2025. The stock surged more than 150% in a short span, drawing significant investor attention.

prnewswire.com

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda. The Company also provided a brief progress update on the expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma.

defenseworld.net

Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week High – Here’s Why

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $89.43 and last traded at $87.41, with a volume of 275711 shares. The stock had previously closed at $82.96. Analyst Ratings Changes INBX has been the subject of several recent

defenseworld.net

Stock Traders Buy High Volume of Inhibrx Biosciences Call Options (NASDAQ:INBX)

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) saw some unusual options trading activity on Friday. Stock traders bought 1,788 call options on the stock. This represents an increase of approximately 103% compared to the average volume of 880 call options. Insiders Place Their Bets In other Inhibrx Biosciences news, major shareholder Global Investors Lp

prnewswire.com

Inhibrx Reports Third Quarter 2025 Financial Results

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

prnewswire.com

Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry/Academia Precision Oncology & Radmed Symposium November 5 th, 2025 – La Jolla, California Title: DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5 th, 2025 Time: 4:45 PM Eastern Standard Time Location: The Alexandria at Torrey Pines, La Jolla, California Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting November 12 th – 15th, 2025 – Boca Raton, Florida Title: The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon Study Lead Author: Robin L. Jones, MD – Medical Oncology, The Royal Marsden and Institute of Cancer Research Format: Presentation Date: Friday, November 14th, 2025 Time: 8:30 AM – 10:00 AM Eastern Standard Time Location: The Boca Raton, Boca Raton, Florida Society for NeuroOncology (SNO) 2025 Annual Meeting November 19 th – 23rd, 2025 – Honolulu, Hawaii Title: The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ Format: Poster Presentation Date: Saturday, November 22 nd, 2025 Time: 4:45 pm – 6:00 PM Eastern Standard Time Location: Hawaii Convention Center, Honolulu, Hawaii; Kamehameha Exhibit Hall II & III The presentation and poster will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations upon commencement of each event.

defenseworld.net

Ethic Inc. Purchases New Shares in Inhibrx Biosciences, Inc. $INBX

Ethic Inc. purchased a new stake in shares of Inhibrx Biosciences, Inc. (NASDAQ: INBX) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 15,739 shares of the company's stock, valued at approximately $227,000. Ethic Inc. owned approximately 0.11% of Inhibrx Biosciences at the end of the

seekingalpha.com

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Inhibrx Biosciences, Inc. delivered strong phase 2 results for ozekibart (INBRX-109) in advanced chondrosarcoma, doubling progression-free survival over placebo. INBX plans to file a Biologics License Application for ozekibart in chondrosarcoma by Q2 2026, with expansion opportunities in colorectal cancer and Ewing sarcoma showing promise. Additional catalysts for INBX stock include upcoming data for INBRX-106, a hexavalent OX40 agonist, targeting HNSCC and NSCLC, expected in Q4 2025.

reuters.com

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended trading.

prnewswire.com

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo Key secondary endpoints reinforce the primary benefit, demonstrating meaningful improvements in disease control and patient quality of life Inhibrx plans to file a BLA in Q2 of 2026 Interim data from expansion cohorts in patients with colorectal cancer and Ewing sarcoma demonstrate high response and disease control rates in difficult-to-treat, heavily pretreated patients Management to host conference call today at 1:30 p.m. Pacific Time, to review the topline results and ongoing cohorts SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.

prnewswire.com

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT – SAN DIEGO , Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m.

prnewswire.com

Inhibrx Reports Second Quarter 2025 Financial Results

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

prnewswire.com

Inhibrx Reports First Quarter 2025 Financial Results

SAN DIEGO , May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

prnewswire.com

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

SAN DIEGO , April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.

prnewswire.com

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

prnewswire.com

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). These results were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Annual Cancers Symposium.

prnewswire.com

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders provided a five-year term loan facility for up to $150 million (the "Credit Facility"). "This enables us strategic flexibility post data readouts expected later this year for our INBRX-109 and INBRX-106 programs," said Kelly Deck, Chief Financial Officer of Inhibrx.

prnewswire.com

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

seekingalpha.com

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

prnewswire.com